These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Bronkhorst IH; Vu TH; Jordanova ES; Luyten GP; Burg SH; Jager MJ Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5370-8. PubMed ID: 22743317 [TBL] [Abstract][Full Text] [Related]
6. Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma. de Lange MJ; Nell RJ; Lalai RN; Versluis M; Jordanova ES; Luyten GPM; Jager MJ; van der Burg SH; Zoutman WH; van Hall T; van der Velden PA Mol Cancer Res; 2018 Dec; 16(12):1902-1911. PubMed ID: 30093564 [TBL] [Abstract][Full Text] [Related]
7. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366 [TBL] [Abstract][Full Text] [Related]
8. HLA expression and tumor-infiltrating immune cells in uveal melanoma. de Waard-Siebinga I; Hilders CG; Hansen BE; van Delft JL; Jager MJ Graefes Arch Clin Exp Ophthalmol; 1996 Jan; 234(1):34-42. PubMed ID: 8750848 [TBL] [Abstract][Full Text] [Related]
9. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. Repp AC; Mayhew ES; Apte S; Niederkorn JY J Immunol; 2000 Jul; 165(2):710-5. PubMed ID: 10878343 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice. Ma D; Niederkorn JY Invest Ophthalmol Vis Sci; 1995 May; 36(6):1067-75. PubMed ID: 7730016 [TBL] [Abstract][Full Text] [Related]
11. Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. Tavera RJ; Forget MA; Kim YU; Sakellariou-Thompson D; Creasy CA; Bhatta A; Fulbright OJ; Ramachandran R; Thorsen ST; Flores E; Wahl A; Gonzalez AM; Toth C; Wardell S; Mansaray R; Radvanyi LG; Gombos DS; Patel SP; Hwu P; Amaria RN; Bernatchez C; Haymaker C J Immunother; 2018; 41(9):399-405. PubMed ID: 29757889 [TBL] [Abstract][Full Text] [Related]
12. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100. Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866 [TBL] [Abstract][Full Text] [Related]
13. Macrophages in uveal melanoma and in experimental ocular tumor models: Friends or foes? Jager MJ; Ly LV; El Filali M; Madigan MC Prog Retin Eye Res; 2011 Mar; 30(2):129-46. PubMed ID: 21129496 [TBL] [Abstract][Full Text] [Related]